A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extended-Release Tablet
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the bioequivalence of two 45-mg hydrocodone
bitartrate extended-release tablets and one 90-mg hydrocodone bitartrate extended-release
tablet.
Phase:
Phase 1
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries